317338-52-6

Upstream product

• 317338-50-4 5-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)-1H-imidazole 
• 172270-85-8 8-(methoxyformylmethylene)-1,4-dioxaspiro[4.5]decane 
• 143948-97-4 8-formylethyl-1,4-dioxaspiro<4.5>decane 
• 317338-46-8 methyl 2-(1,4-dioxaspiro[4.5]decan-8-yl)acetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 317338-50-4 C₁₂H₁₈N₂O₂ 
• 135761-76-1 2-(1,4-dioxaspiro[4.5]decan-8-yl)ethanol 
• 62141-26-8 ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate 
• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 

Downstream Products

• 869501-10-0 4-(4-oxocyclohexylmethyl)imidazole-1-carboxylic acid tert-butyl ester 
• 869501-11-1 4-(4-hydroxycyclohexylmethyl)imidazole-1-carboxylic acid tert-butyl ester 
• 869501-12-2 4-(4-aminocyclohexylmethyl)imidazole-1-carboxylic acid tert-butyl ester 
• 869501-03-1 4-(1H-imidazol-5-ylmethyl)cyclohexylamine dihidrobromide 
• 317339-33-6 C₁₂H₁₉N₃O₃S 

Relevant academic research and scientific papers

New high affinity H3 receptor agonists without a basic side chain

In this study, we replaced the basic amine function of the known histamine H3 receptor agonists imbutamine or immepip with non-basic alcohol or hydrocarbon moieties. All compounds in this study show a moderate to high affinity for the cloned human H3 receptor and, unexpectedly, almost all of them act as potent agonists. Moreover, in the alcohol series, we consistently observed an increased selectivity for the human H3 receptor over the human H4 receptor, but none of the compounds in this series possess increased affinity and functional activity compared to their alkylamine congeners. In this new series of compounds VUF5657, 5-(1H-imidazol-4-yl)-pentan-1-ol, is the most potent histamine H3 receptor agonist (pKi = 8.0 and pEC50 = 8.1) with a 320-fold selectivity at the human H3 receptor over the human H 4 receptor.

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.